MedPath

Randomized phase III Study in patients with ANaplastic glioma of radiotherapy with Temozolomide versus nimustine hydrochloride(ACNU) followed by temozolomide (JCOG1016, SANTA study(P-III))

Phase 3
Recruiting
Conditions
anaplastic glioma
Registration Number
JPRN-UMIN000014104
Lead Sponsor
Japan Clinical Oncology Group (JCOG)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
230
Inclusion Criteria

Not provided

Exclusion Criteria

1) Synchronous or metachronous (within 5 years) malignancy, except for carcinoma in situ or mucosal tumors curatively treated with local therapy 2) Active infection requiring systemic therapy 3) Active infectious meningitis 4) Body temperature >= 38 degrees Celsius at registration 5) Women during pregnancy, possible pregnancy, within 28 days after delivery, or breast-feeding 6) Psychosis or with psychotic symptom 7) Uncontrolled diabetes mellitus or routine administration of insulin 8) Unstable angina within 3 weeks, or with a history of myocardial infarction within 6 months 9) Interstitial pneumonia, fibroid lung, or severe lung emphysema 10) Gadolinium allergy 11) Positive HIV antibody 12) Potitive HBs antigen

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath